Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients (VE-CART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03114826|
Recruitment Status : Unknown
Verified April 2017 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was: Recruiting
First Posted : April 14, 2017
Last Update Posted : April 14, 2017
Renal transplant patients have on average 3-5 times more risk of developing cancer than the general population. This rate can be increased up to 10 to 15 times in some type of cancer like kidney cancer. Among the identified risk factors, immunosuppressants and, in particular, calcineurin inhibitors (ciclosporin and tacrolimus) play a major role in increasing cancers apart from their depressant effects on the immune system.
Calcineurin inhibitors (CCN) are the basis of immunosuppressive therapy in renal transplantation. Several mechanisms have been implicated to explain their pro-oncogenic properties. One related to an increase in VEGF expression seems particularly interesting in the study of renal cell carcinoma in the transplanted patient. Indeed, the physiopathology of kidney cancer has clearly been associated with an increase in the production of VEGF. Furthermore, some polymorphisms of the gene encoding VEGF have already been associated with the survival of patients with renal carcinoma and the circulating level of VEGF in the general population. The search for an association between the polymorphisms of the VEGF gene and renal carcinoma in renal transplant patients could thus identify patients whose risk of renal cell carcinoma (cRCC) post-transplantation is increased. If the involvement of certain polymorphisms in the development of cRCC was confirmed in this population, their research before the introduction of the immunosuppressive treatment would make it possible to direct the choice of treatment towards molecules without pro-oncogenic property in the Patients such as mTOR protein inhibitors (sirolimus, everolimus). This research project is therefore in line with the desire to move towards a more "personalized" medicine that could be beneficial for the patient.
|Condition or disease||Intervention/treatment|
|Polymorphism VEGF Renal Carcinoma Renal Transplantation||Genetic: To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|
|Study Type :||Observational|
|Estimated Enrollment :||272 participants|
|Official Title:||Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients|
|Actual Study Start Date :||October 6, 2016|
|Estimated Primary Completion Date :||October 5, 2019|
|Estimated Study Completion Date :||October 5, 2019|
|Renal cell carcinoma in renal transplant patients||
Genetic: To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker
Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
- Taqman allelic discrimination analysis allows to define, for each polymorphism studied, three genotypes: wild homozygote (WT / WT), heterozygote (WT / M), mutated homozygote (M / M). The presence of renal carcinoma was previously confirmed on biopsy. [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03114826
|Contact: Sandra BODEAU, Drfirstname.lastname@example.org|
|CHU Amiens Picardie||Recruiting|
|Amiens, Picardie, France, 80054|
|Contact: Sandra BODEAU, Dr +33322087029 email@example.com|